Institutional investors purchased a net $1.4 million shares of STML during the quarter ended June 2014. This may signal that the smart money is gaining interest in this company as the 64.68% of shares outstanding that institutional investors hold is actually below the Biotechnology industry average.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
FIDELITY MANAGEMENT & RESEARCH C... Bought 1.5 Million shares of Stemline Therapeutics Inc